These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 25971270)

  • 1. [Multiple myeloma recurring as small intestinal polyposis after autologous hematopoietic stem cell transplantation].
    Otsu K; Seki M; Ogawa S; Miyamoto K; Ito Y; Sakata A; Kurita N; Yokoyama Y; Sakata-Yanagimoto M; Obara N; Hasegawa Y; Chiba S
    Rinsho Ketsueki; 2015 Apr; 56(4):400-5. PubMed ID: 25971270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A case of secondary plasma cell leukemia resistant to novel agents, in which stringent complete remission was achieved and maintained for a long period of time after VAD therapy and tandem autologous transplantation.
    Sekiguchi Y; Shimada A; Wakabayashi M; Sugimoto K; Tomita S; Izumi H; Nakamura N; Sawada T; Ohta Y; Komatsu N; Noguchi M
    Int J Clin Exp Pathol; 2014; 7(9):6313-22. PubMed ID: 25337285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.
    Cavo M; Tacchetti P; Patriarca F; Petrucci MT; Pantani L; Galli M; Di Raimondo F; Crippa C; Zamagni E; Palumbo A; Offidani M; Corradini P; Narni F; Spadano A; Pescosta N; Deliliers GL; Ledda A; Cellini C; Caravita T; Tosi P; Baccarani M;
    Lancet; 2010 Dec; 376(9758):2075-85. PubMed ID: 21146205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of molecular remission rate after bortezomib plus dexamethasone induction treatment and autologous stem cell transplantation in newly diagnosed multiple myeloma patients.
    Silvennoinen R; Kairisto V; Pelliniemi TT; Putkonen M; Anttila P; Säily M; Sikiö A; Opas J; Penttilä K; Kuittinen T; Honkanen T; Lundán T; Juvonen V; Luukkaala T; Remes K
    Br J Haematol; 2013 Feb; 160(4):561-4. PubMed ID: 23206270
    [No Abstract]   [Full Text] [Related]  

  • 5. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
    Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y
    Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complete remission of psoriasis after autologous hematopoietic stem-cell transplantation for multiple myeloma.
    Braiteh F; Hymes SR; Giralt SA; Jones R
    J Clin Oncol; 2008 Sep; 26(27):4511-3. PubMed ID: 18802165
    [No Abstract]   [Full Text] [Related]  

  • 7. Sequential treatment with bortezomib plus dexamethasone followed by autologous hematopoietic stem cell transplantation in patients with multiple myeloma.
    Zheng D; Li J; Huang BH; Liu JR; Zou WY; Su C
    Chin Med J (Engl); 2012 Dec; 125(24):4454-9. PubMed ID: 23253719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intermediate-dose melphalan (100 mg/m2)/bortezomib/thalidomide/dexamethasone and stem cell support in patients with refractory or relapsed myeloma.
    Palumbo A; Avonto I; Bruno B; Falcone A; Scalzulli PR; Ambrosini MT; Bringhen S; Gay F; Rus C; Cavallo F; Falco P; Massaia M; Musto P; Boccadoro M
    Clin Lymphoma Myeloma; 2006 May; 6(6):475-7. PubMed ID: 16796778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Improvement of hepatomegaly after treatment with autologous hematopoietic stem cell transplantation followed by bortezomib and dexamethasone in Bence-Jones protein κ-type of multiple myeloma with systemic amyloidosis].
    Nagamachi Y; Yamauchi N; Muramatsu H; Miyajima N; Inomata H; Okamoto T; Nozawa E; Gotoh Y; Koyama R; Ihara K; Nishisato T; Kato J
    Rinsho Ketsueki; 2015 Mar; 56(3):323-8. PubMed ID: 25876787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two cycles of the PS-341/bortezomib, adriamycin, and dexamethasone combination followed by autologous hematopoietic cell transplantation in newly diagnosed multiple myeloma patients.
    Lee JH; Lee JH; Kim DY; Kim SD; Choi Y; Kang YA; Seol M; Lee KH
    Eur J Haematol; 2012 Jun; 88(6):478-84. PubMed ID: 22364526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early response-based intensification of primary therapy in newly diagnosed multiple myeloma patients who are eligible for autologous stem cell transplantation: phase II study.
    Ahn SY; Jung SH; Joo YD; Lee WS; Lee SM; Choi CW; Kim SJ; Kim K; Lee JJ;
    Ann Hematol; 2014 Sep; 93(9):1571-7. PubMed ID: 24728664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I trial of first-line bortezomib/thalidomide plus chemotherapy for induction and stem cell mobilization in patients with multiple myeloma.
    Badros A; Goloubeva O; Fenton R; Rapoport AP; Akpek G; Harris C; Ruehle K; Westphal S; Meisenberg B
    Clin Lymphoma Myeloma; 2006 Nov; 7(3):210-6. PubMed ID: 17229337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bortezomib in relapsed multiple myeloma complicated by extramedullary plasmacytomas.
    Hughes M; Micallef-Eynaud P
    Clin Lab Haematol; 2006 Aug; 28(4):267-9. PubMed ID: 16898968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of transplant-eligible symptomatic multiple myeloma].
    Nakaseko C
    Rinsho Ketsueki; 2014 Oct; 55(10):2016-26. PubMed ID: 25297767
    [No Abstract]   [Full Text] [Related]  

  • 15. [Outcome of bortezomib plus chemotherapy with or without stem cell transplantation for treatment of multiple myeloma].
    Wang YF; Deng SH; Wu T; Xu Y; Zou DH; Wang Y; Zhao YZ; Qiu LG
    Zhonghua Xue Ye Xue Za Zhi; 2008 Jun; 29(6):397-400. PubMed ID: 19031743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase II trial of weekly bortezomib and dexamethasone in veterans with newly diagnosed multiple myeloma not eligible for or who deferred autologous stem cell transplantation.
    Girnius SK; Lee S; Kambhampati S; Rose MG; Mohiuddin A; Houranieh A; Zimelman A; Grady T; Mehta P; Behler C; Hayes TG; Efebera YA; Prabhala RH; Han A; Yellapragada SV; Klein CE; Roodman GD; Lichtenstein A; Munshi NC
    Br J Haematol; 2015 Apr; 169(1):36-43. PubMed ID: 25572917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study.
    Kaufman JL; Nooka A; Vrana M; Gleason C; Heffner LT; Lonial S
    Cancer; 2010 Jul; 116(13):3143-51. PubMed ID: 20564642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect of bortezomib on the efficiency of hematopoietic stem cell mobilization in patients with multiple myeloma].
    Pokrovskaia OS; Mendeleeva LP; Urnova ES; Gaponova TV; Gal'tseva IV; Kuz'mina LA; Akhundova FM; Kalinin NN; Gretsov EM; Parovichnikova EN; Savchenko VG
    Ter Arkh; 2012; 84(7):35-41. PubMed ID: 23038970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential bortezomib, dexamethasone, and thalidomide maintenance therapy after single autologous peripheral stem cell transplantation in patients with multiple myeloma.
    Sahebi F; Frankel PH; Farol L; Krishnan AY; Cai JL; Somlo G; Thomas SH; Reburiano E; Popplewell LL; Parker PM; Spielberger RT; Kogut NM; Karanes C; Htut M; Ruel C; Duarte L; Murata-Collins JL; Forman SJ
    Biol Blood Marrow Transplant; 2012 Mar; 18(3):486-92. PubMed ID: 22198542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma.
    Leleu X; Fouquet G; Hebraud B; Roussel M; Caillot D; Chrétien ML; Arnulf B; Szalat R; Garderet L; Benajiba L; Pegourie B; Regny C; Royer B; Caulier A; Stoppa AM; Garciaz S; Touzeau C; Chaleteix C; Fermand JP; Loiseau HA; Facon T; Attal M; Moreau P;
    Leukemia; 2013 Nov; 27(11):2242-4. PubMed ID: 23558525
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.